Tazorac
(Tazarotene)ApprovedSmall molecule
Tazarotene is a retinoid medication used to treat acne and psoriasis by reducing skin cell overgrowth and inflammation. It is also used to minimize facial wrinkles and skin discoloration by thickening the outer layers of skin.[2] Tazorac is currently approved and in use across 3 indications[4].[1]
Tazorac is one of 130 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Approved.
3
Indications
11
Total Trials
0
Active Trials
129
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
107 competitors in Psoriasis Vulgaris
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyPhase 3
Cimzia
UCBPhase 3
Tazorac
BBausch Health Americas, Inc.
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Sorilux
LEO PharmaPhase 3
Orencia
Bristol-Myers SquibbPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Asmanex
NovartisPhase 2
LEO 43204
LEO PharmaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acne Vulgaris3 trials
Skin Cancer2 trials
Skin2 trials
Cutaneous T-cell lymphoma1 trial
Psoriasis Vulgaris1 trial
Excimer Laser With Topical Agents in Psoriasis Vulgaris
Unknown status·—·Phase 4·NCT05555797·30 enrolled
Regulatory
FDA Approval Timeline[5]
Jun 13, 1997
TAZORAC
NDA NDA020600
Sep 30, 2002
AVAGE
NDA NDA021184
May 11, 2012
FABIOR
NDA NDA202428
Dec 18, 2019
ARAZLO
NDA NDA211882
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tazorac drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tazarotene. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.